Protagonist Therapeutics Inc (NASDAQ:PTGX) reached a new 52-week high during trading on Thursday . The company traded as high as $19.81 and last traded at $19.71, with a volume of 3381 shares traded. The stock had previously closed at $19.62.
PTGX has been the topic of a number of research reports. Nomura Instinet raised their price target on Protagonist Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Nomura raised their target price on Protagonist Therapeutics from $29.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. SVB Leerink raised their target price on Protagonist Therapeutics from $17.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, May 22nd. HC Wainwright restated a “buy” rating and issued a $28.00 price objective (up from $23.00) on shares of Protagonist Therapeutics in a report on Wednesday, May 13th. Finally, BidaskClub upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 22nd. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.58.
The firm has a market capitalization of $670.63 million, a PE ratio of -7.69 and a beta of 1.30. The company has a debt-to-equity ratio of 0.03, a quick ratio of 6.15 and a current ratio of 6.15. The company’s fifty day moving average price is $16.83 and its two-hundred day moving average price is $11.96.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BVF Inc. IL grew its stake in shares of Protagonist Therapeutics by 241.9% in the 2nd quarter. BVF Inc. IL now owns 2,367,288 shares of the company’s stock valued at $41,806,000 after buying an additional 1,674,858 shares in the last quarter. FMR LLC increased its stake in shares of Protagonist Therapeutics by 26.2% in the 2nd quarter. FMR LLC now owns 5,165,205 shares of the company’s stock valued at $91,217,000 after purchasing an additional 1,071,061 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new position in shares of Protagonist Therapeutics in the 2nd quarter valued at $17,898,000. RTW Investments LP increased its stake in shares of Protagonist Therapeutics by 27.2% in the 2nd quarter. RTW Investments LP now owns 3,383,208 shares of the company’s stock valued at $59,747,000 after purchasing an additional 722,816 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Protagonist Therapeutics by 241.6% in the 1st quarter. JPMorgan Chase & Co. now owns 883,013 shares of the company’s stock valued at $6,234,000 after purchasing an additional 624,546 shares during the last quarter. Hedge funds and other institutional investors own 85.21% of the company’s stock.
Protagonist Therapeutics Company Profile (NASDAQ:PTGX)
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.
Further Reading: What are the benefits of a balanced fund?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.